Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.
Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, Jakkula LR, Wang NJ, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A, Spellman PT, Gray JW, van't Veer LJ.
Daemen A, et al. Among authors: natrajan r.
Breast Cancer Res Treat. 2012 Sep;135(2):505-17. doi: 10.1007/s10549-012-2188-0. Epub 2012 Aug 9.
Breast Cancer Res Treat. 2012.
PMID: 22875744
Free PMC article.